Pyxis Oncology Inc
Research Pyxis Oncology Inc (PYXS) on Bullrun: market cap USD 194.11M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPYXS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 194.11M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 23.27M
- Free cash flow-USD 26.00M
Valuation Snapshot
latest market cap is USD 194.11M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 13.86M | -USD 79.62M | -USD 63.51M | 82.8% | -1.28 | USD 15.42M | USD 18.67M | USD 53.41M |
| FY2024 | USD 16.15M | -USD 77.33M | -USD 57.91M | 97.1% | -1.32 | USD 19.47M | USD 20.20M | USD 120.75M |
| FY2023 | n/a | -USD 73.79M | -USD 77.44M | n/a | -1.85 | USD 9.66M | USD 21.33M | USD 125.70M |
| FY2022 | n/a | -USD 120.72M | -USD 95.73M | n/a | -3.65 | USD 179.29M | USD 15.68M | USD 160.82M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 194.11M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 72.09M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 93.55M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 79.78M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 47.03M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 353.49M | n/a | n/a | n/a |
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Pyxis Oncology Inc's market cap?
Pyxis Oncology Inc's market capitalization is USD 194.11M.
What does Pyxis Oncology Inc do?
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an.